Heart Disease & Cardiology Clinical Trials Update: Week 40, 2026

Published October 2, 2026 — 5 trials covered

By Victor Lafforgue, Founder of TrialsAlert. Blog posts are AI-drafted from ClinicalTrials.gov source data and reviewed by the editorial team. See our editorial policy for details.

VictORION-INCLUSION: Evaluating Inclisiran for Cholesterol Management in Heart Disease

This study is exploring inclisiran, a newer treatment designed to lower cholesterol in adults with atherosclerotic cardiovascular disease. By helping patients achieve their cholesterol goals more easily, inclisiran may reduce the risk of heart attacks and strokes. The trial is taking place at several locations in the United States and is enrolling patients who have a high risk of heart problems.

Vericiguat and Reverse Remodeling Indices in Heart Failure

This trial is testing vericiguat, a medication for adults with stable heart failure where the heart’s pumping ability is reduced. It aims to see if vericiguat can improve heart function and reverse some of the damage caused by heart failure. Conducted in Slovenia, this study offers hope for additional treatment options for people already receiving standard heart failure care.

Withdrawal of Heart Failure Treatment in Patients With Non-ischemic Cardiomyopathy Who Have Been Super-responders to Cardiac Resynchronization Therapy

This research is looking at whether patients with a specific type of heart muscle disease who have responded very well to a device therapy can safely stop taking some heart failure medications. If successful, it could reduce the number of daily pills for these patients without harming their heart health. The study is recruiting in Spain and includes careful heart imaging and genetic testing to select participants.

Flecainide Safety in Patients With Coronary Artery Disease and Atrial Fibrillation

This trial compares the safety of flecainide, a drug that controls irregular heartbeats, to standard treatments in adults with both atrial fibrillation and stable coronary artery disease. The goal is to determine if flecainide can be a safe alternative, potentially offering patients more choices for managing their heart rhythm problems. The study is underway in Belgium and monitors patients regularly for at least one year.

A Study to Investigate LDL-cholesterol Lowering With Inclisiran Compared to Bempedoic Acid in Patients With Atherosclerotic Cardiovascular Disease

This study compares two cholesterol-lowering drugs, inclisiran and bempedoic acid, to see which better reduces LDL cholesterol in adults with cardiovascular disease. Results from this trial, conducted in Germany with over 400 participants, may guide future treatment decisions for patients needing extra help controlling their cholesterol.

TrialsAlert subscribers received the full impact-classified briefing and doctor-ready report this week. Get weekly briefings at trialsalert.com.